Literature DB >> 25041017

High frequency of TP53 but not K-ras gene mutations in Bolivian patients with gallbladder cancer.

Takao Asai1, Ernesto Loza, Guido Villa-Gomez Roig, Yoichi Ajioka, Yasuo Tsuchiya, Masaharu Yamamoto, Kazutoshi Nakamura.   

Abstract

Although genetic characteristics are considered to be a factor influencing the geographic variation in the prevalence of gallbladder cancer (GBC), they have not been well studied in Bolivia, which has a high prevalence rate of GBC. The purpose of this study was to examine the frequency of TP53 and K-ras mutations in Bolivian patients with GBC and to compare them with our previous data obtained in other high-GBC-prevalence countries, namely Japan, Chile, and Hungary. DNA was extracted from cancer sites in paraffin-embedded tissue from 36 patients using a microdissection technique. TP53 mutations at exons 5 to 8 and K-ras mutations at codons 12, 13 and 61 were examined using direct sequencing techniques. The data obtained were compared with those in the other high-GBC-prevalence countries. Of the 36 patients, 18 (50.0%) had a TP53 mutation (one mutation in each of 17 patients and three mutations in one patient), and only one (2.8%) had a K-ras mutation. Of the 20 TP53 mutations, 12 were of the transition type (60.0%). This rate was significantly lower than that in Chile (12/12, P<0.05). In addition, three mutations were of the CpG transition type (15.0%), which is a feature of endogenous mutation. All three were found in the hot spot region of the TP53 gene. In contrast, G:C to T:A transversion was found in Bolivia, suggesting the presence of exogenous carcinogens. Our findings suggest that the development of GBC in Bolivia is associated with both exogenous carcinogens and endogenous mechanisms. The identification of an environmental risk factor for GBC is needed to confirm these findings.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25041017     DOI: 10.7314/apjcp.2014.15.13.5449

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  5 in total

1.  Meta-signature of mutated genes in gallbladder cancer: evidence based high throughput screening assays.

Authors:  Kai Qu; Xing Zhang; Ruixia Cui; Chang Liu
Journal:  Ann Transl Med       Date:  2016-06

2.  MAP kinase and mammalian target of rapamycin are main pathways of gallbladder carcinogenesis: results from bioinformatic analysis of next generation sequencing data from a hospital-based cohort (NCT05404347).

Authors:  Monika Rajput; Satyavjiay Chigurupati; Roli Purwar; Mridula Shukla; Manoj Pandey
Journal:  Mol Biol Rep       Date:  2022-08-26       Impact factor: 2.742

3.  Gallbladder Carcinoma in the United States: A Population Based Clinical Outcomes Study Involving 22,343 Patients from the Surveillance, Epidemiology, and End Result Database (1973-2013).

Authors:  Christine S M Lau; Aleksander Zywot; Krishnaraj Mahendraraj; Ronald S Chamberlain
Journal:  HPB Surg       Date:  2017-05-30

Review 4.  Overview of current targeted therapy in gallbladder cancer.

Authors:  Xiaoling Song; Yunping Hu; Yongsheng Li; Rong Shao; Fatao Liu; Yingbin Liu
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

5.  Identification of Altered Genes in Gallbladder Cancer as Potential Driver Mutations for Diagnostic and Prognostic Purposes: A Computational Approach.

Authors:  Vívian D'Afonseca; Ariel D Arencibia; Alex Echeverría-Vega; Leslie Cerpa; Juan P Cayún; Nelson M Varela; Marcela Salazar; Luis A Quiñones
Journal:  Cancer Inform       Date:  2020-05-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.